Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial

Clinical Neuropharmacology
Jaewon YangSeung-Hyun Kim


The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design. Patients aged 18 to 65 years with schizophrenia were randomly assigned to blonanserin or risperidone treatment for 8 weeks. The efficacy was assessed using the mean change in Positive and Negative Syndrome Scale score total scores from baseline to week 8. Safety assessments included monitoring of vital signs, a physical examination, laboratory tests, and adverse events. Of 206 randomly enrolled patients, 103 receiving blonanserin and 103 receiving risperidone were included in the analysis. In this study, noninferiority between blonanserin and risperidone was demonstrated. The mean change in the Positive and Negative Syndrome Scale total score at the final evaluation time point was -23.48 +/- 19.73 for the blonanserin group and -25.40 +/- 18.38 for the risperidone group. Adverse events, which occurred less frequently in the blonanserin than in the risperidone group, included dysarthria (P = 0.0288), dizziness (P = 0.0139), increased alanine aminotransferase and aspartate aminotransferase (P = 0.0095 and P = 0.0032, respectively), and inc...Continue Reading


Dec 5, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Jong-Hoon KimYong Sik Kim
Jan 1, 1963·Acta Pharmacologica Et Toxicologica·A CARLSSON, M LINDQVIST
Jan 27, 2005·The Journal of Clinical Psychiatry·Stephen M Stahl
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Dec 29, 2005·European Psychiatry : the Journal of the Association of European Psychiatrists·José Luis R MartinEnric Alvarez
Aug 23, 2006·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·Krishnan RamaswamyHenry A Nasrallah
Apr 7, 2007·Diabetes & Metabolism·A J Scheen, M A De Hert
May 6, 2008·Journal of Clinical Psychopharmacology·Steven G PotkinCurt D Wolfgang


Apr 3, 2013·European Journal of Clinical Pharmacology·Melvin GeorgeSteven Aibor Dkhar
Oct 9, 2013·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Ying ZhouPei Hu
Oct 7, 2010·Psychiatry and Clinical Neurosciences·Hidehiro AndohHideo Matsumoto
Mar 19, 2011·Psychiatry and Clinical Neurosciences·Yoshiteru TakekitaToshihiko Kinoshita
May 17, 2011·Psychiatry and Clinical Neurosciences·Koji KatoHideo Matsumoto
Apr 26, 2014·PloS One·Maarten BakMarjan Drukker
Jun 15, 2013·Neuropsychiatric Disease and Treatment·Tomomi TenjinNoboru Yamaguchi
Dec 1, 2012·Acta Neuropsychiatrica·Manabu TakakiYosuke Uchitomi
Dec 21, 2013·Expert Opinion on Pharmacotherapy·Naren P Rao, Gary Remington
Jan 28, 2014·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Aran Min, Daeho Kim
Jan 27, 2012·Human Psychopharmacology·Tomomi TenjinNoboru Yamaguchi
May 20, 2014·Psychiatry and Clinical Neurosciences·Yuriko NinomiyaNoboru Yamaguchi
Mar 9, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Natalia I BrzozowskaJonathon C Arnold
Jul 30, 2019·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Young Sup WooWon-Myong Bahk
Dec 17, 2014·Journal of Clinical Psychopharmacology·Yutaka Mizuki, Manabu Takaki
Jul 17, 2013·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Sakae TakahashiMakoto Uchiyama
Jun 21, 2011·Psychiatry and Clinical Neurosciences·Naohiro KurotakiHiroki Ozawa
Jan 29, 2016·Clinical Neuropharmacology·Yasuhide NagoshiKenji Fukui
Dec 18, 2014·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Manabu TakakiYosuke Uchitomi
Jun 22, 2018·Annals of General Psychiatry·Eun Hyun SeoHyung-Jun Yoon

Related Concepts

Dose-Response Relationship, Drug
Double-Blind Method
Factor Construct Rating Scales (Fcrs)
Antipsychotic Effect
Weight Gain

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.